Premium
Initial improvements when converting eyes with treatment‐resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks
Author(s) -
Jørstad Øystein Kalsnes,
Faber Rowan Thomas,
Moe Morten Carstens
Publication year - 2015
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.12681
Subject(s) - aflibercept , ranibizumab , medicine , bevacizumab , macular degeneration , ophthalmology , visual acuity , surgery , chemotherapy